Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: Results from a phase 2, randomized controlled study

N. Ács, Chris O’Brien, Ping Jiang, Joshua Burke, Roland Jimenez, Elizabeth Garner, Kristof Chwalisz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosisassociated pain. Methods: In this multicenter, double-blind study, women with laparoscopically confirmed endometriosis were randomized to oral elagolix 150 or 250 mg once daily, placebo or 3.75 mg LA intramuscularly (i.m.) monthly for 12 weeks. Placebo and LA patients were re-randomized to elagolix, and elagolix patients continued treatment for another 12 weeks. Results: Baseline demographics were similar among groups (mean age 31.7 years). Significantly greater reductions in monthly mean pelvic pain compared with placebo (p

Original languageEnglish
Pages (from-to)56-62
Number of pages7
JournalJournal of Endometriosis and Pelvic Pain Disorders
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Endometriosis
Gonadotropin-Releasing Hormone
Leuprolide
Pain
Placebos
Acetates
Therapeutics
Pelvic Pain
Double-Blind Method
Estradiol
Age Groups
Demography
elagolix
Safety

Keywords

  • Elagolix
  • Endometriosis
  • GnRH antagonist
  • Leuprorelin acetate
  • Pelvic pain

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist : Results from a phase 2, randomized controlled study. / Ács, N.; O’Brien, Chris; Jiang, Ping; Burke, Joshua; Jimenez, Roland; Garner, Elizabeth; Chwalisz, Kristof.

In: Journal of Endometriosis and Pelvic Pain Disorders, Vol. 7, No. 2, 01.04.2015, p. 56-62.

Research output: Contribution to journalArticle

Ács, N. ; O’Brien, Chris ; Jiang, Ping ; Burke, Joshua ; Jimenez, Roland ; Garner, Elizabeth ; Chwalisz, Kristof. / Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist : Results from a phase 2, randomized controlled study. In: Journal of Endometriosis and Pelvic Pain Disorders. 2015 ; Vol. 7, No. 2. pp. 56-62.
@article{4cf256e062f24a9ab5f375fd8a6d1c3a,
title = "Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist: Results from a phase 2, randomized controlled study",
abstract = "Purpose: Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosisassociated pain. Methods: In this multicenter, double-blind study, women with laparoscopically confirmed endometriosis were randomized to oral elagolix 150 or 250 mg once daily, placebo or 3.75 mg LA intramuscularly (i.m.) monthly for 12 weeks. Placebo and LA patients were re-randomized to elagolix, and elagolix patients continued treatment for another 12 weeks. Results: Baseline demographics were similar among groups (mean age 31.7 years). Significantly greater reductions in monthly mean pelvic pain compared with placebo (p",
keywords = "Elagolix, Endometriosis, GnRH antagonist, Leuprorelin acetate, Pelvic pain",
author = "N. {\'A}cs and Chris O’Brien and Ping Jiang and Joshua Burke and Roland Jimenez and Elizabeth Garner and Kristof Chwalisz",
year = "2015",
month = "4",
day = "1",
doi = "10.5301/je.5000211",
language = "English",
volume = "7",
pages = "56--62",
journal = "Journal of Endometriosis",
issn = "2035-9969",
publisher = "Wichtig Publishing",
number = "2",

}

TY - JOUR

T1 - Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist

T2 - Results from a phase 2, randomized controlled study

AU - Ács, N.

AU - O’Brien, Chris

AU - Jiang, Ping

AU - Burke, Joshua

AU - Jimenez, Roland

AU - Garner, Elizabeth

AU - Chwalisz, Kristof

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose: Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosisassociated pain. Methods: In this multicenter, double-blind study, women with laparoscopically confirmed endometriosis were randomized to oral elagolix 150 or 250 mg once daily, placebo or 3.75 mg LA intramuscularly (i.m.) monthly for 12 weeks. Placebo and LA patients were re-randomized to elagolix, and elagolix patients continued treatment for another 12 weeks. Results: Baseline demographics were similar among groups (mean age 31.7 years). Significantly greater reductions in monthly mean pelvic pain compared with placebo (p

AB - Purpose: Elagolix is a novel, oral GnRH antagonist that dose-dependently suppresses estradiol levels. This study evaluated safety and efficacy of elagolix vs. leuprorelin acetate (LA) and placebo in women with endometriosisassociated pain. Methods: In this multicenter, double-blind study, women with laparoscopically confirmed endometriosis were randomized to oral elagolix 150 or 250 mg once daily, placebo or 3.75 mg LA intramuscularly (i.m.) monthly for 12 weeks. Placebo and LA patients were re-randomized to elagolix, and elagolix patients continued treatment for another 12 weeks. Results: Baseline demographics were similar among groups (mean age 31.7 years). Significantly greater reductions in monthly mean pelvic pain compared with placebo (p

KW - Elagolix

KW - Endometriosis

KW - GnRH antagonist

KW - Leuprorelin acetate

KW - Pelvic pain

UR - http://www.scopus.com/inward/record.url?scp=84941216848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941216848&partnerID=8YFLogxK

U2 - 10.5301/je.5000211

DO - 10.5301/je.5000211

M3 - Article

AN - SCOPUS:84941216848

VL - 7

SP - 56

EP - 62

JO - Journal of Endometriosis

JF - Journal of Endometriosis

SN - 2035-9969

IS - 2

ER -